Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences insider transactions by CFO Andrew D. Dickinson: The filing shows a grant of 3,696 restricted stock units (RSUs) on 09/10/2025, each convertible into one share and subject to a four-year vesting schedule (25% at one year, then 6.25% quarterly). The filing also reports a sale of 1,751 shares on 09/10/2025 at $115.25 per share. After these transactions, Mr. Dickinson beneficially owned 162,055 shares directly and had 3,696 RSUs outstanding, representing 31,219 total shares when combining vested holdings and unvested RSUs.
Daniel P. O'Day, Chairman & CEO and director of Gilead Sciences, reported a sale of 10,000 shares of GILD common stock on 08/28/2025 at a price of $113.63 per share. After the reported sale, Mr. O'Day beneficially owned 595,725 shares. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025, and the Form 4 was signed by Edward S. Son by power of attorney on 08/29/2025. The document contains no additional transactions, derivatives, or explanatory financial data beyond these disclosure items.
Form 144 filing for Gilead Sciences (GILD) reports proposed and recent insider sales of common stock by Daniel O'Day. The filing shows an intended sale of 10,000 shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $1,136,300 and an approximate sale date of 08/28/2025. The shares were originally acquired as restricted stock on 03/01/2022. The filer also reported three recent sales by the same person: 10,000 shares on 07/28/2025 for $1,139,369, 10,000 shares on 06/30/2025 for $1,104,483, and 10,000 shares on 05/30/2025 for $1,104,192. The filing lists 1,240,806,916 shares outstanding.
Johanna Mercier, Chief Commercial Officer of Gilead Sciences (GILD), reported multiple transactions on 08/15/2025 executed under a Rule 10b5-1 trading plan adopted Feb 20, 2025. The filing shows a series of option-related acquisitions and open-market sales in common stock: total reported sales on that date equal 28,000 shares at prices ranging roughly from $117.91 to $119.01, and multiple option exercises/acquisitions at an exercise price of $66.64. Following the reported transactions, the filing lists beneficial ownership levels of common stock as low as 114,168 shares and various counts of options/derivatives remaining outstanding. The Form 4 also discloses that the related options have a four-year vesting schedule with 25% vesting after one year and the remainder vesting quarterly thereafter.
Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences (GILD), reported an insider sale on Form 4. The filing shows a sale of 2,500 shares of Gilead common stock on 08/15/2025 at a price of $118.53 per share, leaving Mr. Dickinson with 160,110 shares beneficially owned after the transaction. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on 08/29/2024. The Form 4 was signed by Edward S. Son by power of attorney for Mr. Dickinson and dated 08/18/2025.
Form 144 filing for Gilead Sciences (GILD) shows an insider intends to sell 2,500 common shares through Morgan Stanley Smith Barney on 08/15/2025, with an aggregate market value of $296,325 and the shares listed for sale on NASDAQ. The filing identifies prior acquisitions of the shares as restricted stock granted on 03/10/2024 (1,200 shares) and 03/10/2023 (1,300 shares). The notice also lists sales by the same person during the past three months totaling 5,000 shares with aggregate cash proceeds of approximately $553,000. The filer signs a representation that they are not aware of undisclosed material adverse information about the issuer.
Gilead Sciences insider notice for proposed Rule 144 sale. The filing reports a proposed sale of 28,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $3,318,924.65 and the company’s outstanding shares listed as 1,240,806,916. The filer shows recent acquisitions including a 25,000-share stock option exercise dated 08/15/2025, 2,394 performance shares (01/31/2024) and 606 restricted shares (12/10/2023). The form also lists multiple dispositions by Johanna Mercier in the past three months, with individual sales and gross proceeds disclosed for each trade.
Gilead Sciences filed a Form 13F reporting its institutional holdings as manager. The filing lists 14 holdings with a total reported market value of $1,280,204,668. The report is signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, dated 08-14-2025.